Senseonics Holdings, Inc. (SENS)

$0.34

Market is closed - opens 7 PM, 11 Sep 2024

Performance

  • $0.33
    $0.34
    $0.34
    downward going graph

    3.68%

    Downside

    Day's Volatility :3.85%

    Upside

    0.18%

    downward going graph
  • $0.32
    $0.75
    $0.34
    downward going graph

    5.88%

    Downside

    52 Weeks Volatility :57.33%

    Upside

    54.67%

    downward going graph

Returns

PeriodSenseonics Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-20.37%
4.7%
0.0%
6 Months
-46.9%
5.1%
0.0%
1 Year
-48.15%
16.6%
0.0%
3 Years
-91.75%
15.6%
-20.6%

Highlights

Market Capitalization
172.7M
Book Value
$0.0
Earnings Per Share (EPS)
-0.13
PEG Ratio
0.0
Wall Street Target Price
1.4
Profit Margin
0.0%
Operating Margin TTM
-400.68%
Return On Assets TTM
-34.8%
Return On Equity TTM
-125.3%
Revenue TTM
24.0M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
17.9%
Gross Profit TTM
2.7M
EBITDA
-72.4M
Diluted Eps TTM
-0.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.13
EPS Estimate Next Year
-0.12
EPS Estimate Current Quarter
-0.03
EPS Estimate Next Quarter
-0.03

Analyst Recommendation

Sell
    11%Buy
    33%Hold
    55%Sell
Based on 9 Wall street analysts offering stock ratings for Senseonics Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
2
Hold
3
3
3
Sell
5
5
5

Analyst Forecast

What analysts predicted

Upside of 311.76%

Current $0.34
Target $1.40

Company Financials

FY18Y/Y Change
Revenue
18.9M
↑ 196.77%
Net Income
-94.0M
↑ 59.0%
Net Profit Margin
-496.86%
↑ 430.51%
FY19Y/Y Change
Revenue
21.3M
↑ 12.63%
Net Income
-126.2M
↑ 34.33%
Net Profit Margin
-592.62%
↓ 95.76%
FY20Y/Y Change
Revenue
4.9M
↓ 76.77%
Net Income
-191.0M
↑ 51.33%
Net Profit Margin
-3.9K%
↓ 3267.23%
FY21Y/Y Change
Revenue
13.7M
↑ 176.32%
Net Income
-317.8M
↑ 66.36%
Net Profit Margin
-2.3K%
↑ 1536.04%
FY22Y/Y Change
Revenue
16.4M
↑ 19.85%
Net Income
142.1M
↓ 144.72%
Net Profit Margin
867.16%
↑ 3190.97%
FY23Y/Y Change
Revenue
22.4M
↑ 36.62%
Net Income
-60.4M
↓ 142.49%
Net Profit Margin
-269.73%
↓ 1136.89%
Q1 FY23Q/Q Change
Revenue
4.1M
↓ 25.74%
Net Income
17.7M
↓ 856.3%
Net Profit Margin
427.97%
↑ 469.99%
Q2 FY23Q/Q Change
Revenue
4.1M
↓ 0.27%
Net Income
-20.4M
↓ 215.35%
Net Profit Margin
-494.98%
↓ 922.95%
Q3 FY23Q/Q Change
Revenue
6.1M
↑ 47.77%
Net Income
-24.1M
↑ 18.02%
Net Profit Margin
-395.33%
↑ 99.65%
Q4 FY23Q/Q Change
Revenue
8.0M
↑ 31.7%
Net Income
-17.2M
↓ 28.68%
Net Profit Margin
-214.07%
↑ 181.26%
Q1 FY24Q/Q Change
Revenue
5.0M
↓ 37.15%
Net Income
-18.9M
↑ 9.81%
Net Profit Margin
-374.02%
↓ 159.95%
Q2 FY24Q/Q Change
Revenue
4.9M
↓ 3.61%
Net Income
-20.3M
↑ 7.47%
Net Profit Margin
-417.0%
↓ 42.98%
FY18Y/Y Change
Total Assets
160.0M
↑ 248.19%
Total Liabilities
88.7M
↑ 129.37%
FY19Y/Y Change
Total Assets
132.6M
↓ 17.11%
Total Liabilities
141.4M
↑ 59.45%
FY20Y/Y Change
Total Assets
35.9M
↓ 72.91%
Total Liabilities
180.0M
↑ 27.26%
FY21Y/Y Change
Total Assets
198.9M
↑ 453.84%
Total Liabilities
384.5M
↑ 113.59%
FY22Y/Y Change
Total Assets
177.7M
↓ 10.68%
Total Liabilities
180.2M
↓ 53.12%
FY23Y/Y Change
Total Assets
138.2M
↓ 22.21%
Total Liabilities
64.8M
↓ 64.07%
Q1 FY23Q/Q Change
Total Assets
158.5M
↓ 10.77%
Total Liabilities
94.1M
↓ 47.81%
Q2 FY23Q/Q Change
Total Assets
153.4M
↓ 3.26%
Total Liabilities
100.8M
↑ 7.18%
Q3 FY23Q/Q Change
Total Assets
154.1M
↑ 0.46%
Total Liabilities
102.0M
↑ 1.17%
Q4 FY23Q/Q Change
Total Assets
138.2M
↓ 10.28%
Total Liabilities
64.8M
↓ 36.5%
Q1 FY24Q/Q Change
Total Assets
126.5M
↓ 8.47%
Total Liabilities
69.9M
↑ 7.92%
Q2 FY24Q/Q Change
Total Assets
111.6M
↓ 11.82%
Total Liabilities
73.3M
↑ 4.91%
FY18Y/Y Change
Operating Cash Flow
-90.8M
↑ 62.85%
Investing Cash Flow
19.4M
↓ 246.88%
Financing Cash Flow
192.0M
↑ 166.4%
FY19Y/Y Change
Operating Cash Flow
-136.0M
↑ 49.88%
Investing Cash Flow
-1.0M
↓ 105.38%
Financing Cash Flow
96.2M
↓ 49.87%
FY20Y/Y Change
Operating Cash Flow
-67.4M
↓ 50.44%
Investing Cash Flow
-181.0K
↓ 82.68%
Financing Cash Flow
-10.1M
↓ 110.53%
FY21Y/Y Change
Operating Cash Flow
-56.1M
↓ 16.83%
Investing Cash Flow
-148.7M
↑ 82081.77%
Financing Cash Flow
220.1M
↓ 2272.59%
FY22Y/Y Change
Operating Cash Flow
-66.3M
↑ 18.25%
Investing Cash Flow
26.9M
↓ 118.07%
Financing Cash Flow
41.8M
↓ 81.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-19.8M
↑ 14.15%
Investing Cash Flow
29.9M
↑ 307.44%
Financing Cash Flow
-807.0K
↓ 107.8%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.0M
↓ 9.39%
Investing Cash Flow
-4.1M
↓ 113.61%
Financing Cash Flow
5.5M
↓ 784.76%

Technicals Summary

Sell

Neutral

Buy

Senseonics Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Senseonics Holdings, Inc.
Senseonics Holdings, Inc.
-16.26%
-46.9%
-48.15%
-91.75%
-71.96%
Stryker Corporation
Stryker Corporation
10.37%
0.94%
19.75%
31.06%
67.96%
Boston Scientific Corp.
Boston Scientific Corp.
7.45%
23.41%
49.56%
83.54%
97.58%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
1.94%
-26.45%
-10.77%
-44.73%
-8.17%
Abbott Laboratories
Abbott Laboratories
5.62%
-5.27%
11.14%
-11.6%
36.83%
Medtronic Plc
Medtronic Plc
10.72%
5.13%
10.43%
-31.45%
-16.37%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Senseonics Holdings, Inc.
Senseonics Holdings, Inc.
8.16
NA
0.0
-0.13
-1.25
-0.35
NA
0.0
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Senseonics Holdings, Inc.
Senseonics Holdings, Inc.
Sell
$172.7M
-71.96%
8.16
0.0%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
67.96%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
97.58%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-8.17%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
36.83%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.37%
30.16
12.06%

Insights on Senseonics Holdings, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 8.02M → 4.86M (in $), with an average decrease of 20.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -17.19M → -20.28M (in $), with an average decrease of 8.6% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.5% return, outperforming this stock by 97.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 83.5% return, outperforming this stock by 175.3%

Company Information

senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm"​) system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Organization
Senseonics Holdings, Inc.
Employees
132
CEO
Dr. Timothy T. Goodnow Ph.D.
Industry
Electronic Technology

Discover More

FAQs